These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20927697)

  • 41. Great(er) expectations.
    Lauriello J
    Am J Psychiatry; 2007 Mar; 164(3):377-9. PubMed ID: 17329458
    [No Abstract]   [Full Text] [Related]  

  • 42. How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?
    Riedel M; Strassnig M; Müller N; Zwack P; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Apr; 255(2):143-8. PubMed ID: 15549345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study.
    Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Degner D; Buchkremer G; Gastpar M; Möller HJ; Riedel M
    Eur Psychiatry; 2009 Dec; 24(8):501-6. PubMed ID: 19559572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Age of illness onset and schizophrenic symptomatology during an inpatient washout period.
    Sharma RP; Dowd SM; Davis JM; Janicak PG
    Schizophr Res; 1996 Jul; 20(3):295-300. PubMed ID: 8827856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nemonapride for the treatment of schizophrenia.
    Satoh K; Someya T; Shibasaki M
    Am J Psychiatry; 1997 Feb; 154(2):292. PubMed ID: 9016292
    [No Abstract]   [Full Text] [Related]  

  • 46. Sustained remission in drug-free schizophrenic patients.
    Fenton WS; McGlashan TH
    Am J Psychiatry; 1987 Oct; 144(10):1306-9. PubMed ID: 2889376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality-of-life assessment in schizophrenia: the unfulfilled promise.
    Awad AG
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):491-3. PubMed ID: 21958091
    [No Abstract]   [Full Text] [Related]  

  • 48. A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information.
    Goyal N; Gomeni R
    Clin Pharmacol Ther; 2012 Feb; 91(2):215-9. PubMed ID: 22089266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The MATRICS initiative: developing a consensus cognitive battery for clinical trials.
    Green MF; Nuechterlein KH
    Schizophr Res; 2004 Dec; 72(1):1-3. PubMed ID: 15531401
    [No Abstract]   [Full Text] [Related]  

  • 50. Measuring remission in schizophrenia: response to Sethuraman et al., 2005.
    Kujawa M; Bossie CA; Lasser RA
    Schizophr Res; 2006 Mar; 83(1):109-10. PubMed ID: 16423505
    [No Abstract]   [Full Text] [Related]  

  • 51. Participation in clinical trials may improve care of acute schizophrenia inpatients in a general hospital.
    Halbreich U; Smail N; Tu X; Halbreich J
    CNS Spectr; 2008 Sep; 13(9):757-61. PubMed ID: 18849894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Communication disturbances in schizophrenia: a two-process formulation.
    Docherty NM
    Compr Psychiatry; 1995; 36(3):182-6. PubMed ID: 7648840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel approach to measuring response and remission in schizophrenia in clinical trials.
    Aboraya A; Leucht S; Nasrallah HA; Samara M; Haro JM; Elshazly A; Zangeneh M
    Schizophr Res; 2017 Dec; 190():123-128. PubMed ID: 28314680
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantifying clinical relevance in the treatment of schizophrenia.
    Correll CU; Kishimoto T; Nielsen J; Kane JM
    Clin Ther; 2011 Dec; 33(12):B16-39. PubMed ID: 22177377
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical heterogeneity of schizophrenia.
    Dollfus S; Brazo P
    Psychopathology; 1997; 30(5):275-81. PubMed ID: 9353856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Remission in schizophrenia: proposed criteria and rationale for consensus.
    Andreasen NC; Carpenter WT; Kane JM; Lasser RA; Marder SR; Weinberger DR
    Am J Psychiatry; 2005 Mar; 162(3):441-9. PubMed ID: 15741458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
    Howes OD; McCutcheon R; Agid O; de Bartolomeis A; van Beveren NJ; Birnbaum ML; Bloomfield MA; Bressan RA; Buchanan RW; Carpenter WT; Castle DJ; Citrome L; Daskalakis ZJ; Davidson M; Drake RJ; Dursun S; Ebdrup BH; Elkis H; Falkai P; Fleischacker WW; Gadelha A; Gaughran F; Glenthøj BY; Graff-Guerrero A; Hallak JE; Honer WG; Kennedy J; Kinon BJ; Lawrie SM; Lee J; Leweke FM; MacCabe JH; McNabb CB; Meltzer H; Möller HJ; Nakajima S; Pantelis C; Reis Marques T; Remington G; Rossell SL; Russell BR; Siu CO; Suzuki T; Sommer IE; Taylor D; Thomas N; Üçok A; Umbricht D; Walters JT; Kane J; Correll CU
    Am J Psychiatry; 2017 Mar; 174(3):216-229. PubMed ID: 27919182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A carbamazepine trial in chronic, treatment-refractory schizophrenia.
    Sramek J; Herrera J; Costa J; Heh C; Tran-Johnson T; Simpson G
    Am J Psychiatry; 1988 Jun; 145(6):748-50. PubMed ID: 3285702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
    Kemp AS; Schooler NR; Kalali AH; Alphs L; Anand R; Awad G; Davidson M; Dubé S; Ereshefsky L; Gharabawi G; Leon AC; Lepine JP; Potkin SG; Vermeulen A
    Schizophr Bull; 2010 May; 36(3):504-9. PubMed ID: 18723840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A search for responders to niacin supplementation.
    Wittenborn JR
    Arch Gen Psychiatry; 1974 Oct; 31(4):547-52. PubMed ID: 4607587
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.